Literature DB >> 7822812

IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.

A H Rook1, M Kubin, M Cassin, E C Vonderheid, B R Vowels, J T Wolfe, S F Wolf, A Singh, G Trinchieri, S R Lessin.   

Abstract

Cutaneous T cell lymphoma is a lymphoproliferative disorder typically characterized by skin invasion of clonally derived malignant CD4+ lymphocytes that phenotypically resemble mature Th cells. Sezary syndrome (SzS) represents an advanced form of cutaneous T cell lymphoma associated with generalized erythroderma and involvement of the peripheral blood by the malignant cell population. We have previously demonstrated aberrant cytokine production by PBMC in SzS characterized by increased IL-4 and deficient IL-2 and IFN-gamma production, as well as increased expression of mRNA for IL-4 and IL-5 within active skin lesions, suggesting that the clonal T cell population is derived from the Th 2 subset of helper T lymphocytes. These findings have been associated with a constellation of immune abnormalities that have been attributed to the cytokine abnormalities. Because IL-12 is a potent inducer of IFN-gamma production, and causes the activation of cytotoxic lymphocytes, we examined the production of IL-12 by PBMC from SzS patients and whether IL-12 could alter the unfavorable cytokine balance typical of SzS and thus lead to correction of immune defects. Despite normal numbers of peripheral blood monocytes and normal TNF-alpha production, mean Staphyloccus aureus and LPS-induced IL-12 p40 and p70 production by SzS PBMC was significantly decreased compared with PBMC from normal controls. Mean IFN-gamma production by patient PBMC in response to PHA alone was depressed, but increased to levels comparable with normal after addition of 1 ng/ml IL-12. Pretreatment of PBMC for 24 h with IL-12, IFN-alpha, or both together resulted in a decrease in PHA-stimulated IL-4 production from a base line of 1818 pg/ml to 1520, 1350, and 1058 pg/ml, respectively. Lastly, culture of patient PBMC with IL-12 for 24 h also resulted in significant increases in NK activity against K562 cells. These results indicate that PBMC from patients with SzS manifest a defect in IL-12 production and that the cytokine abnormalities associated with SzS can be favorably altered by IL-12.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822812

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Authors:  Alain H Rook; Joel M Gelfand; Joel C Gelfand; Maria Wysocka; Andrea B Troxel; Bernice Benoit; Christian Surber; Rosalie Elenitsas; Marie A Buchanan; Deborah S Leahy; Rei Watanabe; Ilan R Kirsch; Ellen J Kim; Rachael A Clark
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

2.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

3.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

4.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

5.  Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma.

Authors:  M Di Renzo; P Rubegni; G De Aloe; L Paulesu; A L Pasqui; L Andreassi; A Auteri; M Fimiani
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

6.  Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Sasha Stephen; Kelly A Morrissey; Bernice M Benoit; Ellen J Kim; Carmela C Vittorio; Sunita D Nasta; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2011-12-21       Impact factor: 10.047

Review 7.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 8.  Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

Authors:  P C Nowell; J S Moore
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

9.  Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.

Authors:  Tzu-Pei Chang; Ivana Vancurova
Journal:  Biochim Biophys Acta       Date:  2014-07-30

10.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.

Authors:  B N Lee; M Duvic; C K Tang; C Bueso-Ramos; Z Estrov; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1999-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.